Hoedemaeker R - Search Results

1

Detection rates of high-grade prostate cancer during subsequent screening visits. Results of the European Randomized Screening Study for Prostate Cancer.

van der Kwast TH, Ciatto S, Martikainen PM, Hoedemaeker R, Laurila M, Pihl CG, Hugosson J, Neetens I, Nelen V, Di Lollo S, Roobol MJ, Määtänen L, Santonja C, Moss S, Schröder FH. van der Kwast TH, et al. Among authors: hoedemaeker r. Int J Cancer. 2006 May 15;118(10):2538-42. doi: 10.1002/ijc.21667. Int J Cancer. 2006. PMID: 16353141 Free article. Clinical Trial.

2

Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer.

Hoedemaeker RF, Rietbergen JB, Kranse R, van der Kwast TH, Schröder FH. Hoedemaeker RF, et al. World J Urol. 1997;15(6):339-45. doi: 10.1007/BF01300181. World J Urol. 1997. PMID: 9436283 Clinical Trial.

3

Evaluation of prostate needle biopsies in a population-based screening study: the impact of borderline lesions.

Hoedemaeker RF, Kranse R, Rietbergen JB, Kruger AE, Schröder FH, van der Kwast TH. Hoedemaeker RF, et al. Cancer. 1999 Jan 1;85(1):145-52. Cancer. 1999. PMID: 9921986 Clinical Trial.

4

Histopathological prostate cancer characteristics at radical prostatectomy after population based screening.

Hoedemaeker RF, Rietbergen JB, Kranse R, Schröder FH, van der Kwast TH. Hoedemaeker RF, et al. J Urol. 2000 Aug;164(2):411-5. J Urol. 2000. PMID: 10893598 Clinical Trial.

5

Defining the window of opportunity in screening for prostate cancer: validation of a predictive tumor classification model.

Vis AN, Hoedemaeker RF, van der Kwast TH, Schröder FH. Vis AN, et al. Among authors: hoedemaeker rf. Prostate. 2001 Feb 1;46(2):154-62. doi: 10.1002/1097-0045(20010201)46:2<154::aid-pros1019>3.0.co;2-1. Prostate. 2001. PMID: 11170143 Clinical Trial.

6

Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml).

Vis AN, Hoedemaeker RF, Roobol M, van der Kwast TH, Schröder FH. Vis AN, et al. Among authors: hoedemaeker rf. Prostate. 2001 Jun 1;47(4):252-61. doi: 10.1002/pros.1069. Prostate. 2001. PMID: 11398172 Clinical Trial.

7

Pathologic features of prostate cancer found at population-based screening with a four-year interval.

Hoedemaeker RF, van der Kwast TH, Boer R, de Koning HJ, Roobol M, Vis AN, Schröder FH. Hoedemaeker RF, et al. J Natl Cancer Inst. 2001 Aug 1;93(15):1153-8. doi: 10.1093/jnci/93.15.1153. J Natl Cancer Inst. 2001. PMID: 11481387 Free article. Clinical Trial.

8

The predictive value for prostate cancer of lesions that raise suspicion of concomitant carcinoma: an evaluation from a randomized, population-based study of screening for prostate cancer.

Vis AN, Hoedemaeker RF, Roobol M, Schröder FH, van der Kwast TH. Vis AN, et al. Among authors: hoedemaeker rf. Cancer. 2001 Aug 1;92(3):524-34. doi: 10.1002/1097-0142(20010801)92:3<524::aid-cncr1351>3.0.co;2-a. Cancer. 2001. PMID: 11505396

9

The clinical significance of a small focus of well-differentiated carcinoma at prostate biopsy.

Hoedemaeker RF, Van der Kwast TH, Schröder FH. Hoedemaeker RF, et al. BJU Int. 2003 Dec;92 Suppl 2:92-6. doi: 10.1111/j.1465-5101.2003.04406.x. BJU Int. 2003. PMID: 14983963 Clinical Trial.

10

Consistency of prostate cancer grading results in screened populations across Europe.

Van der Kwast TH, Roobol MJ, Wildhagen MF, Martikainen PM, Määtänen L, Pihl CG, Santonja C, Bubendorf L, Neetens I, Di Lollo S, Hoedemaeker RF. Van der Kwast TH, et al. Among authors: hoedemaeker rf. BJU Int. 2003 Dec;92 Suppl 2:88-91. doi: 10.1111/j.1465-5101.2003.04405.x. BJU Int. 2003. PMID: 14986593 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

44 results

Search Page